Benedikt Kramer

Benedikt Kramer

Auto-generated profile, based on publicly available information

Benedikt Kramer

Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Claudia FrickClaudia Frick
Claudia Frick
MMMarcus Müller
Marcus Müller
UWUte Wank
Ute Wank
ATAnke Tropitzsch
Anke Tropitzsch
BKBenedikt Kramer
Benedikt Kramer
HLHubert Löwenheim
Hubert Löwenheim

1 August 2017 in Neuroscience
Verified
Journal Article
Closed access
BKBenedikt Kramer
Benedikt Kramer
ATAnke Tropitzsch
Anke Tropitzsch
MMMarcus Müller
Marcus Müller
HLHubert Löwenheim
Hubert Löwenheim

21 August 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Claudia FrickClaudia Frick
Claudia Frick
SFStefan Fink
Stefan Fink
DSDominik Schmidbauer
Dominik Schmidbauer
FRFrancis Rousset
Francis Rousset
HEHolger Eickhoff
Holger Eickhoff
MMMarcus Müller
Marcus Müller
Background: The spatial gap between cochlear implants (CIs) and the auditory nerve limits frequency selectivity as large populations of spiral ganglion neurons (SGNs) are electrically stimulated synchronously. To improve CI performance, a possible strategy is to promote neurite outgrowth toward the CI, thereby allowing a discrete stimulation of small SGN subpopulations. Brain-derived neurotrophic factor (BDNF) is effective to stimulate neurite outgrowth from SGNs. Method: TrkB (tropomyosin receptor kinase B) agonists, BDNF, and five known small-molecule BDNF mimetics were tested for their efficacy in stimulating neurite outgrowth in postnatal SGN explants. To modulate Trk receptor-mediated effects, TrkB and TrkC ligands were scavenged by an excess of recombinant receptor proteins. The pan-Trk inhibitor K252a was used to block Trk receptor actions. Results: THF (7,8,3′-trihydroxyflavone) partly reproduced the BDNF effect in postnatal day 7 (P7) mouse cochlear spiral ganglion explants (SGEs), but failed to show effectiveness in P4 SGEs. During the same postnatal period, spontaneous and BDNF-stimulated neurite outgrowth increased. The increased neurite outgrowth in P7 SGEs was not caused by the TrkB/TrkC ligands, BDNF and neurotrophin-3 (NT-3). Conclusions: The age-dependency of induction of neurite outgrowth in SGEs was very likely dependent on presently unidentified factors and/or molecular mechanisms which may also be decisive for the age-dependent efficacy of the small-molecule TrkB receptor agonist THF.

29 May 2017 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
BKBenedikt Kramer
Benedikt Kramer
CHClemens Hock
Clemens Hock
JSJohannes David Schultz
Johannes David Schultz
ALAnne Lammert
Anne Lammert
BKBeatrice Kuhlin
Beatrice Kuhlin
CAChristoph Aderhold
Christoph Aderhold
Background: The validation of potential molecular targets in head and neck squamous cell carcinoma (SCC) is mandatory. β-Catenin and E-cadherin are crucial for cancer progression through epithelial–mesenchymal transition. We analyzed the effect of the tyrosine kinase inhibitors nilotinib, dasatinib, erlotinib and gefitinib on β-catenin and E-cadherin expression in SCC with respect to human papillomavirus (HPV) status. Materials and Methods: Expression of β-catenin and E-cadherin in cell lines UMSCC 11A, UMSCC 14C and CERV196 under the influence of tyrosine kinase inhibitors were analyzed by enzyme-linked immunosorbent assay. Results: All agents reduced β-catenin and E-cadherin expression of HPV16-negative cells. Increased E-cadherin expression was observed after treatment with gefitinib and dasatinib in HPV16-positive cells. Conclusion: All substances, nilotinib, dasatinib, erlotinib and gefitinib have a significant impact on β-catenin and E-cadherin expression in both HPV16-positive and HPV16-negative cells in vitro. Alterations of β-catenin and E-cadherin could provide novel insights for future targeted therapies of head and neck SCC.

1 June 2016
Verified
Journal Article
Closed access
BKBenedikt Kramer
Benedikt Kramer
CHClemens Hock
Clemens Hock
RBRichard Birk
Richard Birk
ASAlexander Sauter
Alexander Sauter
BSBoris A. Stuck
Boris A. Stuck
CAChristoph Aderhold
Christoph Aderhold

24 June 2016 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
RBR. Birk
R. Birk
CAC. Aderhold
C. Aderhold
AWA. Wenzel
A. Wenzel
TET. Eschenhagen
T. Eschenhagen
BKB. Kramer
B. Kramer
JSJ. U. Sommer
J. U. Sommer